Genomics of cardiovascular disease

Mount Sinai Journal of Medicine

Volumn 76, Issue 6, 2009, Pages 613-623

  Manace, Leslie Cole ^a   Godiwala, Tapan N ^b   Babyatsky, Mark W ^b  

^a Kaiser Oakland Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiology; Genomics; Pharmacogenetics

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C9; FUROSEMIDE; GLIPIZIDE; GLYCERYL TRINITRATE; HEPARIN; ISOSORBIDE MONONITRATE; MEMBRANE PROTEIN; METOPROLOL; PANTOPRAZOLE; SITAGLIPTIN; TROPONIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT I; WARFARIN;

ACUTE HEART INFARCTION; AGED; ANAMNESIS; ANGIOCARDIOGRAPHY; CARDIOVASCULAR DISEASE; CASE REPORT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DIAPHORESIS; DYSPNEA; ELECTROCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOMICS; GENOTYPE; HEART ATRIUM ARRHYTHMIA; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART PALPITATION; HUMAN; HYPERTENSION; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; REVIEW; RHEUMATIC FEVER; ST SEGMENT ELEVATION; SYSTOLIC HEART FAILURE; T WAVE INVERSION; THORAX PAIN;

CARDIOVASCULAR DISEASES; GENETIC MARKERS; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS; SYNDROME;

EID: 73349133307     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20151     Document Type: Review

References (41)

1. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299: 2027-2036.
2. Biselli PM, Guerzoni AR, de Godoy MF, et al. Genetic polymorphisms involved in folate metabolism and concentrations of methylmalonic acid and folate on plasma homocysteine and risk of coronary artery disease. J Thromb Thrombolysis. doi://10.1007/s11239-009-0321-7. Available at: http://www.springerlink.com.
3. Cohen JC, Boerwinkle E, Mosley Jr, et al. Sequence variations in PCKS9, low LDL, and protection against coronary artery disease. N Engl J Med 2006; 354: 1264-1272.
4. Frikke-Schmidt R, Nordesgaard BG, Stene MCA, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 2525-2531.
5. Liu S, Schmitz C, Stampfer MJ, et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 2002; 161: 469-474.
6. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
7. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med 2008; 358: 169-176.
8. Splawski I, Timothy KW, Tateyama M. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333-1336.
9. Burke A, Creighton W, Mont E. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation 2005; 112: 798-802.
10. Prutkin JM, Sotoodehnia N. Genetics of sudden cardiac arrest. Prog Cardiovasc Dis 2008; 50: 390-403.
11. Makita N. Phenotypic overlap cardiac sodium channelopathies: individual or mutation-specific? Circulation 2009; 73: 810-817.
12. Hirschhorn JN. Genomewide association studies-illuminating biologic pathways. N Engl J Med 2009; 360: 1699-1701.
13. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360: 1696-1698.
14. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007; 316: 1491-1493.
15. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007; 316: 1488-1491.
16. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007; 357: 443-453.
17. Larson MG, Atwood LD, Benjamin EJ, et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet 2007; 8(suppl 1): S5.
18. Schunkert H, Götz A, Braund P, et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 2008; 117: 1675-1684.
19. Anderson JL, Horne BD, Kolek MJ, et al. Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J 2008; 156: 1155-1162.
20. Chen SN, Ballantyne CM, Gotto AM Jr, et al. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovasc Disord 2009; 9: 3.
21. Ye S, Willeit J, Kronenberg F, et al. Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol 2008; 52: 378-384.
22. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448: 353-357.
23. K̈äab S, Darbar D, van Noord C, et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009; 30: 813-819.
24. Juang JM, Chern YR, Tsai CT, et al. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol 2007; 116: 107-112.
25. Newton-Cheh C, Johnson T, Gateva V, et al. Genomewide association study identifies eight loci associated with blood pressure. Nat Genet. doi://10.1038/ng.361. Available at: http://www.nature.com.
26. Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
27. Monraats PS, Pires NM, Agema WR, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005; 112: 2417-2425.
28. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.
29. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
30. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
31. Gurbel PA, Bliden KP, Cohen E, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis 2008; 19: 268-275.
32. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-811.
33. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J AmColl Cardiol 2005; 45: 1157-1164.
34. Szczeklik A, Muisal J, Undas A, et al. Aspirin resistance. J Thromb Haemost 2005; 3: 1655-1662.
35. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
36. Daly AK. Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 2009; 1: 10.
37. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
38. Scott SA, Edelmann L, Kornreich R, et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495-500.
39. Barrans JD, Allen PD, Stamatiou D, et al. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002; 160: 2035-2043.
40. Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 2008; 52: 644-651.
41. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.